ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Phase 2
Completed
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Biological: Eculizumab
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01192399
Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
Completed
- Conditions
- Hemoglobinuria
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 5580
- Registration Number
- NCT01192425
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01193348
Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants
Phase 2
Completed
- Conditions
- Hepatitis C
- Interventions
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT01180790
- Locations
- 🇧🇪
Clinical Trial Site, Gent, Oost-Vlaanderen, Belgium
Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01176266
- Locations
- 🇫🇷
Chu de Toulouse, Toulouse, France
🇷🇺Federal State Budgetary Institution, Moscow, Russian Federation
🇩🇪Universitätskinderklinikum Würzburg, Würzburg, Germany
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
- First Posted Date
- 2010-07-15
- Last Posted Date
- 2019-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 19
- Registration Number
- NCT01163149
- Locations
- 🇨🇦
Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada
🇺🇸Shriner's Hospital for Children, Saint Louis, Missouri, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
Phase 2
Completed
- Conditions
- Hypophosphatasia (HPP)
- Interventions
- Biological: asfotase alfa
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00952484
- Locations
- 🇺🇸
Shriners Hospital for Children, Saint Louis, Missouri, United States
🇨🇦The University of Manitoba Health Services Centre, Winnipeg, Manitoba, Canada
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)
Phase 2
Withdrawn
- Conditions
- Hypophosphatasia
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT00894075
Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2009-03-24
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00867932
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS
- First Posted Date
- 2009-02-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00844844
© Copyright 2025. All Rights Reserved by MedPath